

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ARBUTUS BIOPHARMA CORPORATION)	
and GENEVANT SCIENCES GmbH,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 22-252-MSG
)	
MODERNA, INC. and MODERNATX, INC.,)	REDACTED - PUBLIC VERSION
)	
Defendants.)	
<hr/>		
MODERNA, INC. and MODERNATX, INC.,)	
)	
Counterclaim-Plaintiffs,)	
)	
v.)	
)	
ARBUTUS BIOPHARMA CORPORATION)	
and GENEVANT SCIENCES GmbH,)	
)	
Counterclaim-Defendants.)	

JOINT APPENDIX TO CLAIM CONSTRUCTION BRIEF

John W. Shaw (No. 3362)
Karen E. Keller (No. 4489)
Nathan R. Hoeschen (No. 6232)
Emily S. DiBenedetto (No. 6779)
SHAW KELLER LLP
I.M. Pei Building
1105 North Market Street, 12th Floor
Wilmington, DE 19801
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
nhoeschen@shawkeller.com
edibenedetto@shawkeller.com

Attorneys for Plaintiffs

Jack B. Blumenfeld (No. 1014)
Brian P. Egan (No. 6227)
Travis J. Murray (No. 6882)
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
began@morrisnichols.com
tmurray@morrisnichols.com

Patricia A. Carson
Jeanna M. Wacker
Mark C. McLennan
Nancy Kaye Horstman
Caitlin Dean
Shaoyao Yu
KIRKLAND & ELLIS LLP

David I. Berl
Adam D. Harber
Thomas S. Fletcher
Shaun P. Mahaffy
Jessica Palmer Ryen
Anthony H. Sheh
Jihad J. Komis
Philip N. Haunschild
WILLIAMS & CONNOLLY LLP
680 Maine Avenue SW
Washington, DC 20024
(202) 434-5000

*Attorneys for Plaintiff Genevant
Sciences GmbH*

Daralyn J. Durie
Adam R. Brausa
Eric C. Wiener
Annie A. Lee
Shaelyn K. Dawson
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, CA 94105-2482
(415) 268-6080

Kira A. Davis
MORRISON & FOERSTER LLP
707 Wilshire Boulevard
Los Angeles, CA 90017-3543
(213) 892-5200

David N. Tan
MORRISON & FOERSTER LLP
2100 L Street, NW, Suite 900
Washington, DC 20037
(202) 887-1500

*Attorneys for Plaintiff Arbutus
Biopharma Corporation*

601 Lexington Avenue
New York, NY 10022
(212) 446-4679

Alina Afinogenova
KIRKLAND & ELLIS LLP
200 Clarendon Street 47th Floor
Boston, MA 0211
(617) 385 -7500

Yan-Xin Li
KIRKLAND & ELLIS LLP
555 California Street 27th Floor
San Francisco, CA 94104
(415) 439-1400

Attorneys for Defendants

JOINT APPENDIX TABLE OF CONTENTS

J.A. #	Reference	Page Range (JA00)
1	U.S. Patent No. 8,058,069 (“the ’069 patent”)	JA001 - JA0073
2	U.S. Patent No. 8,492,359 (“the ’359 patent”)	JA0074 - JA00147
3	U.S. Patent No. 8,822,668 (“the ’668 patent”)	JA00148 - JA00222
4	U.S. Patent No. 9,364,435 (“the ’435 patent”)	JA00223 - JA00296
5	U.S. Patent No. 9,504,651 (“the ’651 patent”)	JA00297 - JA00326
6	U.S. Patent No. 11,141,378 (“the ’378 patent”)	JA00327 - JA00403
7	Declaration of Professor David H. Thompson Ph.D. Regarding Claim Construction	JA00404 - JA00479
8	’069 Patent File History, Jan. 31, 2011 Reply to Office Action	JA00480 - JA00491
9	’069 Patent File History, May 12, 2011 Non-Final Rejection	JA00492 - JA00507
10	’069 Patent File History, Aug. 11, 2011 Response	JA00508 - JA00518
11	’069 Patent File History, Sept. 12, 2011 Notice of Allowance	JA00519 - JA00525
12	’378 Patent File History, Apr. 14, 2021 Claims (excerpt)	JA00526 - JA00530
13	’378 Patent File History, June 14, 2021 Non-Final Rejection	JA00531 - JA00544
14	’378 Patent File History, Aug. 20, 2021 Response	JA00545 - JA00556
15	’651 Patent File History, Aug. 14, 2014 Non-Final Rejection	JA00557 - JA00568
16	’651 Patent File History, Oct. 22, 2014 Response & Declaration	JA00569 - JA00595
17	’651 Patent File History, Jan. 5, 2015 Third Party Submission	JA00596 - JA00600

J.A. #	Reference	Page Range (JA00)
18	'651 Patent File History, Feb. 13, 2015 Non-Final Rejection	JA00601 - JA00616
19	'651 Patent File History, May 12, 2015 Response & Declaration	JA00617 - JA00632
20	'651 Patent File History, June 19, 2015 Final Rejection	JA00633 - JA00651
21	'651 Patent File History, Aug. 18, 2015 Response	JA00652 - JA00663
22	'651 Patent File History, Oct. 9, 2015 Non-Final Rejection	JA00664 - JA00673
23	'651 Patent File History, Dec. 14, 2015 Response & Declaration	JA00674 - JA00685
24	'651 Patent File History, Apr. 15, 2016 Rejection	JA00686 - JA00696
25	'651 Patent File History, May 19, 2016 Response & Declaration	JA00697 - JA00708
26	'651 Patent File History, Oct. 3, 2016 Rejection	JA00709 - JA00717
27	'651 Patent File History, Oct. 19, 2016 Notice of Allowance ("NOA")	JA00718 - JA00724
28	'435 Patent Final Written Decision, IPR2018-00739, Paper No. 51 (P.T.A.B. Sept. 11, 2019)	JA00725 - JA00776
29	Declaration of David H. Thompson, Ph.D., IPR2018-00739, Exhibit No. 2009 ("Thompson '435 IPR Decl.")	JA00777 - JA00864
30	Moderna Initial Invalidity Contentions (May 19, 2023) (excerpt) ("Invalidity Contentions") [Moderna Confidential Information Redacted]	JA00865 - JA00869
31	I. MacLachlan, <i>Liposomal Formulations for Nucleic Acid Delivery</i> , Antisense Drug Techs. (2d ed. 2007) ("MacLachlan 2007")	JA00870 - JA00903
32	U.S. Patent No. 5,830,430 ("Unger")	JA00904 - JA00942
33	E. Check, <i>RNA to the rescue?</i> , Nature, vol. 425, pp. 10-12 (2003) ("Check 2003")	JA00943 - JA00945
34	B. Sternberg et al., <i>New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy</i> , FEBS Letters, vol. 356, pp. 361-66 (1994) ("Sternberg 1994")	JA00946 - JA00951

J.A. #	Reference	Page Range (JA00)
35	E. Samaridou et al., <i>Lipid nanoparticles for nucleic acid delivery: Current perspectives</i> , Advanced Drug Delivery Reviews, vols. 154-55, pp. 37-63 (2020) (“Samaridou 2020”)	JA00952 - JA00978
36	J. A. Kulkarni et al., <i>On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA</i> , ACS Nano, vol. 12, pp. 4787-95 (2018) (“Kulkarni 2018”)	JA00979 - JA00987
37	Michael D. Buschmann et al., <i>Nanomaterial Delivery Systems for mRNA Vaccines</i> , Vaccines (Basel), vol. 9, no. 65 pp. 1-30 (Jan. 19, 2021) (“Buschmann 2021”)	JA00988 - JA001017
38	<i>Remington: The Science and Practice of Pharmacy Twentieth Edition</i> (Alfonso R. Gennaro et al. eds., 2000) (“Remington 2000”)	JA001018 - JA001065
39	<i>United States Pharmacopeia, Twenty-third Revision</i> (1995) (“USP 23”)	JA001066 - JA001078
40	U.S. Patent No. 4,737,323	JA001079 - JA001085
41	U.S. Patent Publication 2006/0240554 (“the ’554 publication”)	JA001086 - JA001234
42	P. Tam et al., <i>Stabilized plasmid-lipid particles for systemic gene therapy</i> , Gene Therapy, vol. 7, pp. 1867-74 (2000) (“Tam 2000”)	JA001235 - JA001242
43	J. Heyes et al., <i>Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery</i> , Journal of Controlled Release, vol. 112, pp. 280-90 (2006) (“Heyes 2006”)	JA001243 - JA001253
44	WO 98/51278 (“Semple”)	JA001254 - JA001351
45	U.S. Patent No. 6,734,171 (“Saravolac”)	JA001352 - JA001401
46	Y.P. Zhang et al., <i>Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties</i> , Gene Therapy, vol. 6, pp. 1438-1447 (1999) (“Zhang 1999”)	JA001402 - JA001411
47	J. Heyes et al., <i>Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids</i> , J. Controlled Release, vol. 107, pp. 276-87 (2005) (“Heyes 2005”)	JA001412 - JA001423
48	WO 00/03683	JA001424 - JA001477
49	J. J. Wheeler et al., <i>Stabilized plasmid-lipid particles: construction and characterization</i> , Gene Therapy, vol. 6, pp. 271-281 (1999) (“Wheeler 1999”)	JA00 1478- JA001488

J.A. #	Reference	Page Range (JA00)
50	A. Chonn et al., <i>Recent advances in liposome drug delivery systems</i> , Curr. Opin. Biotech, vol. 6, pp. 698-708 (1995) (“Chonn 1995”)	JA001489 - JA001499
51	K. Mok et al., <i>Stabilized plasmid–lipid particles: factors influencing plasmid entrapment and transfection properties</i> , Biochim Biophys Acta, vol. 1419, pp. 137-150 (1999) (“Mok 1999”)	JA001500 - JA001513
52	U.S. Patent No. 6,287,591 (“the ’591 Patent”)	JA001514 - JA001561
53	U.S. Patent No. 7,901,708 (“the ’708 Patent”)	JA001562 - JA001587
54	European Patent No. 2 279 254 (“EP2279254”)	JA001588 - JA001679
55	’069 Patent File History, Apr. 15, 2009 Claims	JA001680 - JA001832
56	’069 Patent File History, Nov. 12, 2009 Claims	JA001833 - JA001843
57	’069 Patent File History, June 1, 2010 Claims	JA001844 - JA001850
58	’069 Patent File History, July 30, 2010 Non-Final Rejection	JA001851 - JA001866
59	’359 Patent File History, Oct, 5, 2011 Claims	JA001867 - JA001971
60	’359 Patent File History, Mar. 28, 2012 Claims	JA001972 - JA001979
61	’435 Patent File History, Aug. 18, 2014 Claims	JA001980 - JA002122
62	’435 Patent File History, Feb. 26, 2015 Claims	JA002123 - JA002127
63	’668 Patent File History, June 26, 2013 Claims	JA002128 - JA002274
64	’668 Patent File History, Nov. 6, 2013 Claims	JA002275 - JA002283
65	Patent Owner’s Response, IPR2019-00554, Paper 15 (P.T.A.B. Nov. 31, 2019)	JA002284 - JA002357
66	Patent Owner’s Sur-Reply, IPR2019-00554, Paper 30 (P.T.A.B. Mar. 31, 2020)	JA002358 - JA002391

J.A. #	Reference	Page Range (JA00)
67	Declaration of David H. Thompson, Ph.D., IPR2019-00554, Exhibit No. 2004 (“Thompson Decl”)	JA002392 - JA002479
68	Patent Owner’s Response, IPR2018-00739, Paper 24 (P.T.A.B. Dec. 21, 2018)	JA002480 - JA002551
69	Record of Oral Hearing, IPR2018-00680 & IPR2018-00739, Paper 49 (P.T.A.B. June 6, 2019)	JA002552 - JA002684
70	Declaration of Andrew S. Janoff, Ph.D., IPR2018-00739, Exhibit No. 1007	JA002685 - JA002753
71	Liposome Drug Products, FDA Guidance for Industry, IPR2018-00739, Exhibit No. 2013	JA002754 - JA002771
72	Nonconfidential Opening Brief of Cross-Appellant Protiva Biotherapeutics, Inc. (<i>ModernaTX, Inc. v. Protiva Biotherapeutics, Inc.</i> , No. 2020-1184 (Fed. Cir. July 28, 2020) (D.I. 67))	JA002772 - JA002869
73	Reply Brief of Cross-Appellant Protiva Biotherapeutics, Inc. (<i>ModernaTX, Inc. v. Protiva Biotherapeutics, Inc.</i> , No. 2020-1184 (Fed. Cir. Nov. 9, 2020) (D.I. 83))	JA002870 - JA002897
74	Unofficial Transcript, Oral Argument (<i>ModernaTX, Inc. v. Protiva Biotherapeutics, Inc.</i> , No. 2020-1184 (Fed. Cir. Oct. 7, 2021), argument available at https://oralarguments.cafc.uscourts.gov/default.aspx?fl=20-1184_10072021.mp3	JA002898 - JA002925
75	Decision (<i>ModernaTX, Inc. v. Protiva Biotherapeutics, Inc.</i> , No. 2020-1184 (Fed. Cir. Dec. 1, 2021) (D.I.135))	JA002926 - JA002944
76	Protiva Biotherapeutics Inc.’s Response to Oppositions by Merck, Sharp & Dohme Corp. and Moderna TX, Inc. Regarding EP No. 2 279 254 (Sept. 3, 2018)	JA002945 - JA002982
77	ModernaTX, Inc., 3.2.S.2.2 Description of Manufacturing Process and Process Controls (BLA No. 125752) (MRNA-GEN-00034354)	JA002983 - JA002991
78	Moderna Therapeutics Press Release, Moderna Announces \$40 Million in Financing to Advance Development of New Biotherapeutic Modality: Messenger RNA Therapeutics™ (Dec. 6, 2012), Available at: https://www.prnewswire.com/news-releases/moderna-announces-40-million-in-financing-to-advance-development-of-new-biotherapeutic-modality-messenger-rna-therapeutics-182304241.html	JA002992 - JA002996
79	Patent Owner’s Sur-Reply, IPR2018-00739, Paper 34 (P.T.A.B. Apr. 17, 2019)	JA002997 - JA003041
80	Summary table listing the Molar Ratio Patents and related IPR proceedings.	JA003042

J.A. #	Reference	Page Range (JA00)
81	Moderna Experimental Report, DH-07346 (MRNA-GEN-00044173–MRNA-GEN-00044182)	JA003043 - JA003046
82	Petitioner’s Reply to Protiva’s Response, IPR2019-00554, Paper 21 (P.T.A.B. Mar. 2, 2020)	JA003047 - JA003081
83	Petition for <i>Inter Partes</i> Review of U.S. Patent No. 8,058,069, IPR2019-00554, Paper 1 (P.T.A.B. Jan. 9, 2019)	JA003082 - JA003162
84	Declaration of Andrew S. Janoff, Ph.D., IPR2019-00554, Exhibit No. 1008 (P.T.A.B. Jan 2, 2019)	JA003163 - JA003236
85	Declaration of Thomas J. Anchordoquy, Ph.D., IPR2019-00554, Exhibit No. 1020 (P.T.A.B. Mar. 2, 2020)	JA003237 - JA003300
86	Arbutus Biopharma Corp.’s observations on behalf of Opponent-Appellant 2, Appeal No. T0505/20-3.3.08 (Munich, Mar. 22, 2022)	JA003301 - JA003367
87	Merck, Sharp & Dohme Corp.’s Grounds for Opposition Against EP 2 279 254 (Munich, Apr. 5, 2018)	JA003368 - JA003399
88	Deposition Transcript of David H. Thompson, Ph.D. (Nov. 14, 2023)	JA003400 - JA003442
89	Deposition Transcript of David H. Thompson, Ph.D., IPR2019-00554 (Jan. 15, 2020) (excerpt)	JA003443 - JA003451

/s/ Nathan R. Hoeschen

John W. Shaw (No. 3362)
Karen E. Keller (No. 4489)
Nathan R. Hoeschen (No. 6232)
Emily S. DiBenedetto (No. 6779)
SHAW KELLER LLP
I.M. Pei Building
1105 North Market Street, 12th Floor
Wilmington, DE 19801
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
nhoeschen@shawkeller.com
edibenedetto@shawkeller.com
Attorneys for Plaintiffs

/s/ Travis J. Murray

Jack B. Blumenfeld (No. 1014)
Brian P. Egan (No. 6227)
Travis J. Murray (No. 6882)
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
began@morrisnichols.com
tmurray@morrisnichols.com
Attorneys for Defendants

CERTIFICATE OF SERVICE

I hereby certify that on December 20, 2023, this document was served on the persons listed below in the manner indicated:

BY EMAIL:

Jack B. Blumenfeld
Brian P. Egan
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
began@morrisnichols.com

James F. Hurst
KIRKLAND & ELLIS LLP
300 North LaSalle
Chicago, IL 60654
(312) 862-2000
james.hurst@kirkland.com

Alina Afinogenova
KIRKLAND & ELLIS LLP
200 Clarendon Street
Boston, MA 02116
(617) 385-7500
alina.afinogenova@kirkland.com

Patricia A. Carson, Ph.D.
Jeanna M. Wacker
Mark C. McLennan
Nancy Kaye Horstman
Shaoyao Yu
Caitlin Dean
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, NY 10022
(212) 446-4800
patricia.carson@kirkland.com
jeanna.wacker@kirkland.com
mark.mclennan@kirkland.com
kaye.horstman@kirkland.com
shaoyao.yu@kirkland.com
caitlin.dean@kirkland.com

Yan-Xin Li
KIRKLAND & ELLIS LLP
555 California Street, 27th Floor
San Francisco, CA 94104
(415) 439-1400
yanxin.li@kirkland.com

/s/ Nathan R. Hoeschen

John W. Shaw (No. 3362)
Karen E. Keller (No. 4489)
Nathan R. Hoeschen (No. 6232)
Emily S. DiBenedetto (No. 6779)
SHAW KELLER LLP
I.M. Pei Building
1105 North Market Street, 12th Floor
Wilmington, DE 19801
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
nhoeschen@shawkeller.com
edibenedetto@shawkeller.com
Attorneys for Plaintiffs